Risk of valvular heart disease associated with the use of dopamine agonists in Parkinson's disease: A systematic review

Journal of Neural Transmission

Volumn 116, Issue 2, 2009, Pages 179-191

  Steiger, Malcolm ^a   Jost, W ^b   Grandas, F ^c   Van Camp, G ^d  

^a WALTON CENTRE FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

^b DEUTSCHE KLINIK FÜR DIAGNOSTIK   (Germany)

^c HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^d Academic Hospital   (Belgium)

Author keywords

Cardiac valve regurgitation; Dopamine agonists; Parkinson's disease; Valvular heart disease

Indexed keywords

BROMOCRIPTINE MESILATE; CABERGOLINE; DOPAMINE RECEPTOR STIMULATING AGENT; LISURIDE MALEATE; PERGOLIDE MESILATE; PIRIBEDIL; PRAMIPEXOLE; ROPINIROLE; ROTIGOTINE;

AORTA VALVE REGURGITATION; ARTICLE; CARDIOVASCULAR RISK; CLINICAL TRIAL; DISEASE SEVERITY; HEART VALVE REGURGITATION; HUMAN; MITRAL VALVE REGURGITATION; PARKINSON DISEASE; PRIORITY JOURNAL; RESTLESS LEGS SYNDROME; SYSTEMATIC REVIEW; TRICUSPID VALVE REGURGITATION;

DOPAMINE AGONISTS; HEART VALVE DISEASES; HUMANS; PARKINSON DISEASE; RISK FACTORS;

EID: 59849098512     PISSN: 03009564     EISSN: 14351463     Source Type: Journal    
DOI: 10.1007/s00702-008-0179-4     Document Type: Article

References (53)

1. Adler CH, Sethi KD, Hauser RA, Davis TL, Hammerstad, JP, Bertoni et al (1997) Ropinirole for the treatment of early Parkinson's disease. The Ropinirole Study Group. Neurology 49:393-399
2. A Antonini W Poewe 2007 Fibrotic heart-valve reactions to dopamine agonist treatment in Parkinson's disease Lancet Neurol 6 826 829
3. DS Bana PS MacNeal PM LeCompte Y Shah JR Graham 1974 Cardiac murmurs and endocardial fibrosis associated with methysergide therapy Am Heart J 88 640 655
4. DG Baseman PE O'Suilleabhain SC Reimold SR Laskar JG Baseman RB Dewey Jr 2004 Pergolide use in Parkinson disease is associated with cardiac valve regurgitation Neurology 63 301 304
5. ER Brunt DJ Brooks AD Korczyn JL Montastruc F Stocchi 2002 A six-month multicentre, double-blind, bromocriptine-controlled study of the safety and efficacy of ropinirole in the treatment of patients with Parkinson's disease not optimally controlled by l-dopa J Neural Transm 109 489 502
6. V Calomne MJ Dupuis T Muller F Kempinere 2004 Reversible cardiac valve abnormalities with pergolide treatment Rev Neurol (Paris) 160 81 82
7. CE Clarke M Guttman 2002 Dopamine agonist monotherapy in Parkinson's disease Lancet 360 1767 1769
8. HM Connolly JL Crary MD McGoon DD Hensrud BS Edwards WD Edwards 1997 Valvular heart disease associated with fenfluramine-phentermine N Engl J Med 337 581 588
9. J-C Corvol J-B Anzouan-Kacou E Fauveau A-M Bonnet B Lebrun-Vignes C Girault 2007 Heart valve regurgitation, pergolide use, and Parkinson disease Arch Neurol 64 1721 1726
10. GC Cotzias MH Van Woert LM Schiffer 1967 Aromatic amino acids and modification of parkinsonism N Engl J Med 276 374 379
11. G Davey Smith M Egger 1998 Meta-analysis. Unresolved issues and future developments BMJ 316 221 225
12. RB Dewey II SC Reimold PE O'Suilleabhain 2007 Cardiac valve regurgitation with pergolide compared with nonergot agonists in Parkinson disease Arch Neurol 64 377 380
13. V Dhawan P Medcalf F Stegie G Jackson S Basu P Luce 2005 Retrospective evaluation of cardio-pulmonary fibrotic side effects in symptomatic patients from a group of 234 Parkinson's disease patients treated with cabergoline J Neural Transm 112 661 668
14. M Egger GD Smith 1998 Bias in location and selection of studies BMJ 316 61 66
15. CM Flowers JA Racoosin SL Lu JG Beitz 2003 The US Food and Drug Administration's registry of patients with pergolide-associated valvular heart disease Mayo Clin Proc 78 730 731
16. K Grosset F Needleman G Macphee D Grosset 2004 Switching from ergot to nonergot dopamine agonists in Parkinson's disease: a clinical series and five-drug dose conversion table Mov Disord 19 1370 1374
17. M Hendrikx J Van Dorpe W Flameng W Daenen 1996 Aortic and mitral valve disease induced by ergotamine therapy for migraine: a case report and review of the literature J Heart Valve Dis 5 235 237
18. RG Holloway I Shoulson S Fahn K Kieburtz A Lang K Marek 2004 Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial Arch Neurol 61 1044 1053
19. J Horvath RD Fross G Kleiner-Fisman R Lerch H Stalder S Liaudat 2004 Severe multivalvular heart disease: a new complication of the ergot derivative dopamine agonists Mov Disord 19 656 662
20. JG Jollis CK Landolfo J Kisslo GD Constantine KD Davis T Ryan 2000 Fenfluramine and phentermine and cardiovascular findings: effect of treatment duration on prevalence of valve abnormalities Circulation 101 2071 2077
21. S Junghanns JT Fuhrmann G Simonis C Oelwein R Koch RH Strasser 2007 Valvular heart disease in Parkinson's disease patients treated with dopamine agonists: a reader-blinded monocenter echocardiography study Mov Disord 22 234 238
22. G Kenangil S Ozekmekci L Koldas T Sahin E Erginoz 2007 Assessment of valvulopathy in Parkinson's disease patients on pergolide and/or cabergoline Clin Neurol Neurosurg 109 350 353
23. JY Kim EJ Chung SW Park WY Lee 2006 Valvular heart disease in Parkinson's disease treated with ergot derivative dopamine agonists Mov Disord 21 1261 1264
24. A Lieberman A Ranhosky D Korts 1997 Clinical evaluation of pramipexole in advanced Parkinson's disease: results of a double-blind, placebo-controlled, parallel-group study Neurology 49 162 168
25. A Lieberman CW Olanow K Sethi P Swanson CH Waters S Fahn 1998 A multicenter trial of ropinirole as adjunct treatment for Parkinson's disease. Ropinirole Study Group Neurology 51 1057 1062
26. CD Marsden JD Parkes 1977 Success and problems of long-term levodopa therapy in Parkinson's disease Lancet 1 345 349
27. MJ Millan L Maiofiss D Cussac V Audinot JA Boutin A Newman-Tancredi 2002 Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes J Pharmacol Exp Ther 303 791 804
28. JM Miyasaki W Martin O Suchowersky WJ Weiner AE Lang 2002 Practice parameter: initiation of treatment for Parkinson's disease: an evidence-based review: report of the Quality Standards Subcommittee of the American Academy of Neurology Neurology 58 11 17
29. Y Mizuno N Yanagisawa S Kuno M Yamamoto K Hasegawa H Origasa 2003 Randomized, double-blind study of pramipexole with placebo and bromocriptine in advanced Parkinson's disease Mov Disord 18 1149 1156
30. A Newman-Tancredi D Cussac Y Quentric M Touzard L Verriele N Carpentier 2002 Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. III. Agonist and antagonist properties at serotonin, 5-HT(1) and 5-HT(2), receptor subtypes J Pharmacol Exp Ther 303 815 822
31. JG Nutt 1990 Levodopa-induced dyskinesia: review, observations, and speculations Neurology 40 340 345
32. JA Obeso F Grandas J Vaamonde MR Luquin J Artieda G Lera 1989 Motor complications associated with chronic levodopa therapy in Parkinson's disease Neurology 39 11 19
33. R Pahwa SA Factor KE Lyons WG Ondo G Gronseth H Bronte-Stewart 2006 Practice parameter: treatment of Parkinson's disease with motor fluctuations and dyskinesia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology Neurology 66 983 995
34. C Peralta E Wolf H Alber K Seppi S Muller S Bosch 2006 Valvular heart disease in Parkinson's disease vs. controls: an echocardiographic study Mov Disord 21 1109 1113
35. A Pinero P Marcos-Alberca J Fortes 2005 Cabergoline-related severe restrictive mitral regurgitation N Engl J Med 353 1976 1977
36. AM Pritchett JF Morrison WD Edwards HV Schaff HM Connolly RE Espinosa 2002 Valvular heart disease in patients taking pergolide Mayo Clin Proc 77 1280 1286
37. O Rascol DJ Brooks AD Korczyn PP De Deyn CE Clarke AE Lang 2000 A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group N Engl J Med 342 1484 1491
38. MM Redfield WJ Nicholson WD Edwards AJ Tajik 1992 Valve disease associated with ergot alkaloid use: echocardiographic and pathologic correlations Ann Intern Med 117 50 52
39. E Ruzicka H Linkova M Penicka O Ulmanova L Novakova J Roth 2007 Low incidence of restrictive valvulopathy in patients with Parkinson's disease on moderate dose of pergolide J Neurol 254 1575 1578
40. R Schade F Andersohn S Suissa W Haverkamp E Garbe 2007 Dopamine agonists and the risk of cardiac-valve regurgitation N Engl J Med 356 29 38
41. J Schwarz 2003 Rationale for dopamine agonist use as monotherapy in Parkinson's disease Curr Opin Neurol 16 Suppl 1 S27 S33
42. J Serratrice P Disdier G Habib F Viallet PJ Weiller 2002 Fibrotic valvular heart disease subsequent to bromocriptine treatment Cardiol Rev 10 334 336
43. BK Shively CA Roldan EA Gill T Najarian SB Loar 1999 Prevalence and determinants of valvulopathy in patients treated with dexfenfluramine Circulation 100 2161 2167
44. JP Singh JC Evans D Levy MG Larson LA Freed DL Fuller 1999 Prevalence and clinical determinants of mitral, tricuspid, and aortic regurgitation (the Framingham Heart Study) Am J Cardiol 83 897 902
45. DF Stroup JA Berlin SC Morton I Olkin GD Williamson D Rennie 2000 Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group JAMA 283 2008 2012
46. G Van Camp A Flamez B Cosyns J Goldstein C Perdaens D Schoors 2003 Heart valvular disease in patients with Parkinson's disease treated with high-dose pergolide Neurology 61 859 861
47. G Van Camp A Flamez B Cosyns C Weytjens L Muyldermans M Van Zandijcke 2004 Treatment of Parkinson's disease with pergolide and relation to restrictive valvular heart disease Lancet 363 1179 1183
48. EA Waller J Kaplan MG Heckman 2005 Valvular heart disease in patients taking pergolide Mayo Clin Proc 80 1016 1020
49. A Wilke H Hesse G Hufnagel B Maisch 1997 Mitral, aortic and tricuspid valvular heart disease associated with ergotamine therapy for migraine Eur Heart J 18 701
50. M Yamamoto T Uesugi T Nakayama 2006 Dopamine agonists and cardiac valvulopathy in Parkinson disease: a case-control study Neurology 67 1225 1229
51. K Yamashiro M Komine-Kobayashi T Hatano T Urabe H Mochizuki N Hattori 2008 The frequency of cardiac valvular regurgitation in Parkinson's disease Mov Disord 23 935 941
52. R Zanettini A Antonini G Gatto R Gentile S Tesei G Pezzoli 2007 Valvular heart disease and the use of dopamine agonists for Parkinson's disease N Engl J Med 356 39 46
53. WA Zoghbi M Enriquez-Sarano E Foster PA Grayburn CD Kraft RA Levine 2003 Recommendations for evaluation of the severity of native valvular regurgitation with two-dimensional and Doppler echocardiography J Am Soc Echocardiogr 16 777 802